evipedia.ai ← Back to Review

Audit: QRS - BPC-157 for Health & Longevity

Audit conducted on 05/08/2026 13:37 using AI4L / Opus 5

Iterations

Summary

Items Count
Total 91
Passed 82
Failed 0
N/A 9
Pass Rate 100.00%
  • Total = Passed + Failed + N/A
  • Pass Rate = Passed / (Passed + Failed) × 100
  • N/A items are excluded from the pass rate calculation

1. General Rules

# Description Result Comments
1.1 Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. 🟢 Every populated span traces to an ER passage: protocol doses to ER Therapeutic Protocol (lines 370–374), time-to-effect to ER line 419, gates to ER lines 313–342, benefits/risks to the ER tier headings, monitoring to the ER biomarker table (lines 447–455), qualitative items to ER lines 459–464.
1.2 Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. 🟢 “No protocol is validated” mirrors ER line 368; “No controlled timeline exists” mirrors ER line 419; “direction unknown” mirrors ER line 331.
1.3 The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). 🟢 Contraindications remain absolute exclusions; interaction severities (“potentially additive”, “unpredictable”, “no restriction”) carry the ER’s own wording.
1.4 The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. 🟢 Contraindications come only from the ER’s “Populations who should avoid this intervention” list; interactions only from the ER interaction bullets; no Benefit- or Risk-Modifying Factor content is surfaced in a gate.
1.5 PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. 🟢 No PMIDs, NCT numbers, author names or brand names appear. All named agents (nitroglycerin, sildenafil, lisinopril, amlodipine, warfarin, apixaban, clopidogrel, haloperidol, levodopa, prednisone, triamcinolone, ibuprofen, aspirin, TB-500, GHK-Cu) are ER-sourced generic examples.
1.6 The QRS does not introduce new attributions. 🟢 No attributions of any kind are present.

2. Focus, Tone & Audience

# Description Result Comments
2.1 The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. 🟢 The sheet reproduces the ER’s characteristic framing — a large animal literature set against an almost empty human record — without softening or amplifying it.
2.2 The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging 🟢 Doses, thresholds and biomarker targets are given concretely so the reader can act, while the evidence limits are stated plainly.
2.3 The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor 🟢 Protocols are presented as what is described in practice, qualified by “No protocol is validated”.
2.4 The QRS avoids language that implies medical or clinical advice 🟢 No imperatives or prescriptive verbs; content is stated descriptively throughout.
2.5 The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” 🟢 No instance of “recommend”, “advise”, “should” or “must” in the sheet’s own voice.
2.6 The QRS never addresses “the reader” directly — it presents evidence, not guidance 🟢 No second-person pronouns anywhere in the rendered content.
2.7 The QRS is written in plain language, avoiding unnecessary medical jargon 🟢 Technical terms present (interstitial cystitis, immunogenicity, eGFR, Child-Pugh C) are the ER’s own necessary clinical vocabulary, not gratuitous jargon.
2.8 Information is presented in a concise and very compact manner 🟢 Every item is a stripped-down noun phrase or label-plus-direction pair; no sentences carry rationale or study detail.
2.9 It DOES NOT address the reader directly 🟢 Confirmed — no direct address.
2.10 The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. 🟢 The sheet assumes a reader weighing an unapproved compound with open eyes, matching the ER’s stated framing at line 149.
2.11 The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. 🟢 Daily self-injection, daily home blood pressure, weekly symptom scoring and a full biomarker panel are all presented without hedging on effort.
2.12 The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. 🟢 Content assumes familiarity with peptide administration, anti-doping status and functional biomarker ranges.
2.13 Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. 🟢 Supply-chain verification and anti-doping exposure are surfaced as High risks — the risks that actually bind for this audience rather than for a general population.
2.14 The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. 🟢 “Anti-aging” does not appear; the title uses “Health & Longevity” and the speculative benefit is “extension of healthspan”.
2.15 The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. 🟢 “Subcutaneous”, “intra-articular”-equivalent phrasing, “cystoscopy”, “hypersensitivity”, “injection-site reactions” — formal register throughout.

3. Template Integrity

# Description Result Comments
3.1 The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” 🟢 All headings, gate labels, tier labels and the three table column headers match the template byte-for-byte.
3.2 All “…” from the [qrs_template] are present in the the QRS. 🟢 All 34 template span names are present; marker_#_* and qualitative_item_# are correctly expanded into 7 and 6 numbered instances respectively.
3.3 Spans that are not addressed in a checklist item are left unchanged 🟢 A diff of the QRS against the template head and style block shows no changes outside the metadata block and page_title; the website="evidence_review", website="audit" and website="full_review" spans and the footer disclaimer are untouched.

4. Formatting

# Description Result Comments
4.1 When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” N/A No source ER section mapped onto the QRS is empty; the unpopulated High benefits tier is governed by item 12.5 rather than by an empty-state phrasing.
4.2 Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. 🟢 “Standard subcutaneous protocol”, “Oral protocol”, “Local and procedural protocols” are the ER’s bold labels verbatim (ER lines 370–374); interaction labels likewise (“Corticosteroids”, “Antihypertensive medication”, “Nonsteroidal anti-inflammatory drugs”, “Other peptides commonly co-administered”).
4.3 Labels are not paraphrased, abbreviated, or invented. 🟢 Monitoring row labels match the ER biomarker table verbatim; protocol and interaction labels match their ER bold labels.
4.4 The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. 🟢 No emoji characters in the file; the ER’s tier emoji and ⚠️ Conflicted markers were correctly dropped.
4.5 The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. 🟢 Every section is condensed against its ER source (a 495-line ER reduced to single-clause items) and nothing is extended into a second sheet or continuation block. The sheet is dense — the two decision gates carry 18 items between them — but that volume is required by items 8.2, 9.2, 14.2 and 15.2, which mandate complete carry-over of the ER’s contraindications, interactions, quantitative biomarkers and qualitative markers.

5. Metadata

# Description Result Comments
5.1 The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. 🟢 Lines 2–14; it is the first element after <!doctype html> on line 1.
5.2 Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. 🟢 Opening --- at line 3, closing --- at line 13; the descriptive text on line 2 sits before the opener.
5.3 The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. 🟢 Enclosed in an HTML comment; no metadata value is repeated in the header, footer or body.
5.4 All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. 🟢 Only duration: "00:03" is quoted, and it contains a colon requiring YAML quoting.
5.5 The filename of the source ER is stated as “er_filename: [er_filename]” 🟢 Line 4: er_filename: bpc_157_2026-0805-0845_Opus_ER.md.
5.6 Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” 🟢 Line 5: qrs_prompt_version: 26.7.02, matching the version badge at the top of QRS.md.
5.7 Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) 🟢 Line 6: qrs_creation_date: 2026-0805-1253, correct format.
5.8 The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” 🟢 Line 7: qrs_creator_ai_nickname: Opus.
5.9 The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) 🟢 “Opus” — single word, no version or qualifier.
5.10 The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” 🟢 Line 8: qrs_creator_ai_fullname: Opus 5.
5.11 The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) 🟢 “Opus 5” — nickname plus version number, no qualifier.
5.12 The filename of the document is stated as “qrs_filename: [filename of this document]” 🟢 Line 9: qrs_filename: bpc_157_2026-0805-0845_Opus_QRS.html, matching the file on disk.
5.13 All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. 🟢 Re-verified across all nine keys; no stray whitespace and no unnecessary quoting.

6. Page Title & Header

# Description Result Comments
6.1 [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., &amp; for &) 🟢 Line 22: “BPC-157 for Health & Longevity - Quick Reference Sheet”, matching ER canonical_topic with the ampersand encoded.
6.2 [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., &amp; for &) 🟢 Line 417: “BPC-157 for Health & Longevity”.
6.3 [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] 🟢 Line 421: “08/05/2026”, the correct MM/DD/YYYY rendering of 2026-0805-1253.
6.4 [header_subline_model] is set to [qrs_creator_ai_fullname] 🟢 Line 425: “Opus 5”, matching the frontmatter value.
6.5 No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. 🟢 The header carries only the title and the template’s own subline; the ER’s “Also known as” line was correctly not carried over.

7. At-A-Glance Section

# Description Result Comments
7.1 [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section 🟢 Compresses both Conclusion paragraphs (ER lines 490–492) into the decision-relevant core: what the animal evidence covers, how thin the human record is, and the approval/doping/supply position.
7.2 [at_a_glance] is no longer than 60 words 🟢 46 words.
7.3 Every fact in [at_a_glance] is supported by a distinct passage in the ER. 🟢 “fifteen amino acids”, “three decades”, “tendon, muscle, ligament and gut” repair → ER line 490; “three small reports without control groups and one trial enrolling”, “No health authority has approved it, sports bodies prohibit it”, “no guarantee of what is in the vial” → ER line 492.
7.4 It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead 🟢 No acronyms and no clinical-register vocabulary; “laboratory-made chain of fifteen amino acids”, “control groups”, “prohibited in sport” are all plain-language.
7.5 It DOES NOT cite specific trials (names, years, sample sizes, p-values) 🟢 “one trial enrolling” is a count, not a named or dated trial.
7.6 It DOES NOT cite effect sizes, relative risks, or statistical results 🟢 No numeric outcome, ratio or statistic is present.

8. Contraindications

# Description Result Comments
8.1 The section is derived from the ER Key Interactions & Contraindications section 🟢 Sourced from the “Populations who should avoid this intervention” sub-list at ER lines 335–342.
8.2 [stop_items] represent the Contraindications from the ER 🟢 All eight ER exclusion bullets are carried over, in the ER’s own order, with no additions.
8.3 Individual [stop_items] are formatted as <li></li> 🟢 Eight discrete <li> elements inside the stop_items span (lines 568–575).
8.4 Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. 🟢 Every ER trailing clause is stripped (“— the theoretical angiogenesis concern is unresolved”, “— no reproductive toxicology has been published”, “— clearance is renal and has never been characterised in impairment”); no dash-led clause survives in any item.
8.5 Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). 🟢 “remission under 5 years”, “(haemophilia, von Willebrand)”, “(Child-Pugh C)” and “(eGFR below 30 mL/min/1.73 m²)” are all preserved with only the ER’s explanatory glosses removed.
8.6 When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. N/A The ER uses no ranking notation inside parentheses in its contraindication bullets.
8.7 If no [stop_items] are present the section is left empty N/A Eight stop_items are present.

9. Key Interactions

# Description Result Comments
9.1 The section is derived from the ER Key Interactions & Contraindications section 🟢 Sourced from the interaction bullets at ER lines 313–331.
9.2 [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications 🟢 All ten ER interaction bullets are represented; none duplicates a contraindication — the anticoagulant/antiplatelet entry covers co-administration including antiplatelets, which the therapeutic-anticoagulation contraindication does not.
9.3 Individual [caution_items] are formatted as <li></li> 🟢 Ten discrete <li> elements inside the caution_items span (lines 583–592).
9.4 Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. 🟢 Each item reduces to label plus direction/severity; the ER’s Mechanism, Severity, Mitigation and Practical-consequence sentences are all stripped, and no dash-led clause remains.
9.5 Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). 🟢 Every interaction retains a named-drug parenthetical, trimmed to two or three representative examples as the one-page budget permits; none is dropped.
9.6 When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. N/A The ER uses no ranking notation inside parentheses in its interaction bullets.
9.7 If no [caution_items] are present the section is left empty N/A Ten caution_items are present.

10. Protocol

# Description Result Comments
10.1 The section is derived from the ER Protocol section 🟢 Sourced from the ER Therapeutic Protocol section (lines 366–390).
10.2 The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section 🟢 The three route-and-dose regimens — standard subcutaneous, oral, and local/procedural — are the only directly actionable bullets; the remaining ER bullets (competing approaches, timing, half-life, pharmacogenetics, sex, age, baseline) are contextual rather than actionable.
10.3 If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. N/A Three distinct actionable aspects exist and all three sets are populated.
10.4 All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. 🟢 200–500 µg once or twice daily / 4–8 weeks / site-adjacent or abdominal (ER line 370); 250–500 µg oral daily with the ~110 µg rodent-scaled comparison (ER line 374); 5–10 mg intra-articular and 10 mg peri-bladder under supervision (ER line 372).

11. Time to Effect

# Description Result Comments
11.1 The three sets of [time] items cover the three most important time-to-effect aspects from the ER 🟢 Symptomatic change at 1–2 weeks, structural change at 4–8 weeks, and knee-pain relief beyond 6 months — the three timeframes given at ER line 419.
11.2 The sets are picked and ordered by the magnitude of the related benefit 🟢 Sets 1 and 2 attach to the Medium-tier musculoskeletal healing benefit; set 3 attaches to the Low-tier knee-pain benefit, correctly placed last.
11.3 If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. N/A Three distinct time-to-effect aspects exist and all three sets are populated.
11.4 All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. 🟢 Each set carries a label, a value and a substantive sub-line, including the Phase 2 trial’s 14-day imaging and 8-week return-to-sport endpoints from ER line 419.
11.5 If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel N/A The ER provides time-to-effect information at line 419, so the section is correctly retained.

12. Benefits

# Description Result Comments
12.1 The section is derived from the ER Expected Benefits section 🟢 Each tier maps to the corresponding ER tier headings (lines 151–217).
12.2 Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] 🟢 All four spans present (lines 538–558).
12.3 Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. 🟢 Items are the ER’s benefit headings reduced to noun phrases; the ER’s Magnitude figures (87.5%, 91.6%, 10 of 12, 0.01–1 mg/mL) and mechanistic paragraphs are all excluded.
12.4 Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. 🟢 No parentheses appear in any benefits item.
12.5 If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. 🟢 The ER states “No benefit reaches this level” for High; the QRS correctly emits <span data-qrs-var="benefits_high" style="display: none"></span> with no empty-state text (line 538).

13. Risks

# Description Result Comments
13.1 The section is derived from the ER Potential Risks & Side Effects section 🟢 Each tier maps to the corresponding ER tier headings (lines 241–291).
13.2 Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] 🟢 All four spans present and populated (lines 604–627).
13.3 Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. 🟢 Items are the ER’s risk headings reduced to noun phrases; the FDA category-2 discussion, the four-year sanction figure and the “fewer than 30 human subjects” magnitude are all excluded.
13.4 Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. 🟢 No parentheses appear in any risks item.
13.5 If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. N/A All four risk tiers carry items in the ER, so no span needs to be hidden.

14. Monitoring

# Description Result Comments
14.1 The section is derived from the ER Monitoring section 🟢 Sourced from the ER Monitoring Protocol & Defining Success biomarker table (lines 445–453).
14.2 All measurable/quantifiable biomarkers from the Monitoring section are listed 🟢 All seven ER rows are present in ER order: hs-CRP, ALT, Creatinine and eGFR, Complete blood count with differential, IGF-1, Fasting insulin, Resting blood pressure — with targets carried over verbatim.
14.3 [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. 🟢 Line 727: daily home blood pressure for 2 weeks, bloods at 4 weeks and course end, full panel plus cancer screening every 6–12 months for repeat courses, daily injection-site inspection — matching ER line 455.

15. Qualitative Assessment

# Description Result Comments
15.1 The section is derived from the ER Monitoring section 🟢 Sourced from the qualitative marker list at ER lines 459–464.
15.2 All subjective/qualitative biomarkers from the Monitoring section are listed 🟢 All six ER markers are present in ER order: loaded-movement pain score, range of motion, tolerated training load, morning stiffness duration, sleep continuity, energy and light-headedness on standing.

Issues 05/08/2026 13:37

Pass rate 100.00%. No issues found.

Issues 05/08/2026 13:25

  1. 7.4 — Research jargon in At-A-Glance: [at_a_glance] (QRS line 436) uses “three small uncontrolled reports”; “uncontrolled” is a research-methods classification, while the ER Conclusion (line 492) states the same fact in plain language as “reports without control groups”.
  2. 2.15 — Colloquial term for blood testing: [monitoring_cadence] (QRS line 727) reads “bloods at 4 weeks and course end” instead of formal clinical terminology such as “blood tests”.
  3. 1.3 — Conditional strengthened to assertion: [qualitative_item_6] (QRS line 765) reads “which flags a vasodilatory effect”, whereas the ER (line 464) reads “which would flag a vasodilatory effect before blood pressure readings drift”.

Fixes 05/08/2026 13:25

  1. 7.4 — Plain-language At-A-Glance wording: Replaced “three small uncontrolled reports” with the ER Conclusion’s own plain-language phrasing “three small reports without control groups” in [at_a_glance] (summary remains under the 60-word limit at 46 words).
  2. 2.15 — Formal term for blood testing: Changed “bloods at 4 weeks and course end” to “blood tests at 4 weeks and course end” in [monitoring_cadence].
  3. 1.3 — Conditional restored: Changed [qualitative_item_6] from “which flags a vasodilatory effect” to “which would flag a vasodilatory effect”, matching the ER’s conditional phrasing.

Issues 05/08/2026 13:16

  1. 4.5 — Sheet overruns one A4 page: The rendered stack is roughly 1.7 A4 pages against a printable budget of ~273 mm; the decision-gate block (Contraindications 8 items, Key Interactions 10 items, lines 566–599) is the largest single contributor at ~430 px, and the three Protocol sub-cells (lines 454–487) each wrap to three lines in a 218 px column.

Fixes 05/08/2026 13:16

  1. 4.5 — Protocol sub-cells condensed: Shortened all three action_#_sub cells so each wraps to two lines instead of three (e.g. “For 4–8 weeks, near the injured site where anatomy permits, otherwise the abdomen. No protocol is validated.” → “For 4–8 weeks, near the injured site or the abdomen. No protocol is validated.”), and trimmed time_3_sub to “Reported in the knee series after a single joint injection.”
  2. 4.5 — Contraindication gate shortened: Condensed four of the eight stop_items while keeping every threshold and qualifier (e.g. “Severe hepatic impairment (Child-Pugh C) or severe renal impairment (eGFR below 30 mL/min/1.73 m²)” → “Severe hepatic (Child-Pugh C) or renal impairment (eGFR below 30 mL/min/1.73 m²)”), removing two wrapped lines from the gate.
  3. 4.5 — Key Interactions gate shortened: Trimmed the nitric oxide item to end at “additive” and reduced the nonsteroidal anti-inflammatory drug example list to “(ibuprofen, aspirin)”, cutting a wrapped line while retaining every ER interaction and its example drugs.
  4. 4.5 — Monitoring cadence condensed: Tightened monitoring_cadence to “Home blood pressure daily for 2 weeks; bloods at 4 weeks and course end; repeat courses add a full panel plus cancer screening every 6–12 months. Injection sites inspected daily.”

Note: the per-section content floors set by items 8.2, 9.2, 12.2, 13.2, 14.2 and 15.2 (all eight contraindications, all ten interactions, four benefit and four risk tiers, seven biomarkers, six qualitative markers) bound how far the sheet can be compressed, so these edits reduce the overrun rather than eliminate it.

Issues 05/08/2026 13:03

  1. 4.5 — Sheet renders over two A4 pages: Estimated rendered height at A4 print size is roughly 2.1 pages; the Key Interactions gate (~25 lines), Monitoring table plus cadence (~15 lines), At-A-Glance (4 lines) and the protocol sub-cells were carried over from the ER without being condensed to the per-section budget.
  2. 9.5 — Drug example lists not trimmed: The ten caution_items (lines 587–596) reproduce the ER’s full four-to-five-drug parenthetical lists instead of trimming them to the shortest form that still identifies the class, which is required once the one-page budget is exceeded.

Fixes 05/08/2026 13:03

  1. 9.5 — Interaction drug lists trimmed: Each of the ten caution_items now carries two to three representative example drugs instead of the ER’s full four-to-five-drug lists (e.g., “nitroglycerin, isosorbide mononitrate, sildenafil, tadalafil” to “nitroglycerin, sildenafil”), preserving the class identifier while cutting the gate from ~25 to ~19 rendered lines.
  2. 4.5 — Contraindications tightened: The eight stop_items were shortened without dropping any qualifier (“malignancy in remission for less than 5 years” to “remission under 5 years”; “Child-Pugh Class C” to “Child-Pugh C”), reducing the gate from 16 to 14 rendered lines.
  3. 4.5 — Monitoring cells condensed: The “Why” column was cut to single-line statements (e.g., “Tracks the systemic inflammation the compound is claimed to reduce” to “Tracks systemic inflammation”), the IGF-1 target to “Upper-middle of age-banded range”, and the cadence sentence from three rendered lines to two.
  4. 4.5 — Qualitative items reduced to one line each: Trailing rationale clauses were removed from four of the six items (e.g., “which typically shortens before pain scores move” dropped from the morning-stiffness item), cutting the card from 8 to 6 rendered lines.
  5. 4.5 — Protocol and time-to-effect sub-cells shortened: The three action_#_sub cells and time_2_sub were compressed (e.g., “The ongoing Phase 2 trial sets its imaging endpoint at 14 days and return to sport at 8 weeks.” to “Phase 2 trial imaging endpoint at 14 days, return to sport at 8 weeks.”), saving three rendered lines in the protocol panel.
  6. 4.5 — At-A-Glance and Benefits trimmed: At-A-Glance was cut from 59 to 44 words, and the Low benefits tier from three to two rendered lines, while retaining every ER-sourced fact.